BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Fact Check: Some Bridge Photos Circulating Do NOT Show The Hongqi Bridge That Collapsed In Southwest China Nov. 11, 2025 - 2Famous Rough terrain Vehicles for 2024
- 3New Cheetos and Doritos will be free of artificial dyes
- 4Language Learning Applications for Voyagers
- 5Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- Most loved Broiled Chicken: Which Chain Rules?
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Vote In favor of Your Favored Web based Dating Application
- Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- Ukrainian foreign minister appeals for funds for drones
- Independence from the rat race: How to Save and Contribute Shrewdly
- Vote in favor of Your #1 BWM Vehicles
